Vectus Biosystems (ASX:VBS) ROCE %: 0.00% (As of Dec. 2025)


ASX:VBS Vectus Biosystems Ltd ASX:VBS
18 GF Score
Price A$0.16
! 2 Warning Signs
View Full Analysis

What is Vectus Biosystems ROCE %?

Vectus Biosystems ASX:VBS +3.23% 18 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates ASX:VBS with a GF Score™ of 18/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vectus Biosystems's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.

Vectus Biosystems  (ASX:VBS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vectus Biosystems ROCE % Related Terms

Vectus Biosystems ROCE % Historical Data

* Premium members only.

The historical data trend for Vectus Biosystems's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vectus Biosystems ROCE % Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -125.37 -712.74 -7,050.00 -92.33 -246.59

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -78.95 -118.77 -231.43 -769.32 0.00
ASX:VBS
18GF Score
Vectus Biosystems Ltd ASX:VBS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vectus Biosystems ROCE % Calculation

Vectus Biosystems's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-1.773/( ( (2.026 - 0.535) + (0.783 - 0.836) )/ 2 )
=-1.773/( (1.491+-0.053)/ 2 )
=-1.773/0.719
=-246.59 %

Vectus Biosystems's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-1.42/( ( (0.783 - 0.836) + (0.462 - 0.797) )/ 2 )
=-1.42/( ( -0.053 + -0.335 )/ 2 )
=-1.42/-0.194
=0 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Vectus Biosystems (ASX:VBS) has a ROCE % of 0.00% as of Dec. 2025.
Is Vectus Biosystems' ROCE % too high?
Vectus Biosystems' current ROCE % is 0.00%. Overall, Vectus Biosystems has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Vectus Biosystems' ROCE % compare to VRTX and REGN?
Vectus Biosystems' ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Vectus Biosystems's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectus Biosystems stock overvalued right now?
Vectus Biosystems (ASX:VBS) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Vectus Biosystems' overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Vectus Biosystems (ASX:VBS), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vectus Biosystems Business Description

Address 26-34 Dunning Avenue, Unit 5, Ground Floor, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
18GF Score

Get the complete analysis for ASX:VBS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.16
Price